TCM
BCRX icon

TD Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

TD Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-20
Closed – – 121
2021
Q4 		$0 Hold
20
– – ﹤0.01% 374
2021
Q3 		$0 Hold
20
– – ﹤0.01% 364
2021
Q2 		$0 Buy
+20
New +$272 ﹤0.01% 344

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TD Capital Management's BCRX Position: Q1 2022 in Review

TD Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2022, closing a stake of 20 shares.

TD Capital Management first reported a position in BCRX in Q2 2021 and held it in 3 quarters. The position peaked at $0 in Q4 2021. 233 funds tracked by Wall St. Rank hold BCRX as of Q1 2022.

  • TD Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • TD Capital Management sold 20 BioCryst Pharmaceuticals shares in Q1 2022.
  • TD Capital Management first reported a position in BioCryst Pharmaceuticals in Q2 2021 and held it in 3 quarters.
  • TD Capital Management's BioCryst Pharmaceuticals position peaked at $0 in Q4 2021.
  • 233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2022.

Based on TD Capital Management's 13F filing for Q1 2022, filed 18 May 2022.